ic 261 has been researched along with gemcitabine in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Ammerpohl, O; Bohm, B; Brockschmidt, C; Eismann, T; Giamas, G; Henne-Bruns, D; Hillenbrand, A; Hirner, H; Huber, N; Kalthoff, H; Knippschild, U; Leithäuser, F; Radunsky, B; Trauzold, A | 1 |
1 other study(ies) available for ic 261 and gemcitabine
Article | Year |
---|---|
Anti-apoptotic and growth-stimulatory functions of CK1 delta and epsilon in ductal adenocarcinoma of the pancreas are inhibited by IC261 in vitro and in vivo.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; Carcinoma, Pancreatic Ductal; Casein Kinase 1 epsilon; Casein Kinase Idelta; Cell Proliferation; Deoxycytidine; Drug Evaluation, Preclinical; fas Receptor; Gemcitabine; Humans; Indoles; Lymphatic Metastasis; Mice; Mice, SCID; Neoplasm Transplantation; Pancreatic Neoplasms; Phloroglucinol; Transplantation, Heterologous; Tumor Cells, Cultured | 2008 |